Sensei Biotherapeutics Stock (NASDAQ:SNSE)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.50

52W Range

$0.38 - $1.94

50D Avg

$0.58

200D Avg

$0.82

Market Cap

$12.73M

Avg Vol (3M)

$52.06K

Beta

0.03

Div Yield

-

SNSE Company Profile


Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

28

IPO Date

Feb 04, 2021

Website

SNSE Performance


SNSE Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-37.06M$-50.19M$-37.48M
Net Income$-34.10M$-48.81M$-37.46M
EBITDA$-37.06M$-50.19M$-36.00M
Basic EPS-$-1.59$-1.35
Diluted EPS-$-1.59$-1.35

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
DBTXDecibel Therapeutics, Inc.
VORVor Biopharma Inc.
LABPLandos Biopharma, Inc.
EVAXEvaxion Biotech A/S